Hidden Endocrine Complications in Rothmund Thomson Syndrome A Rare Sibling Case Study

Introduction

Understanding Rothmund-Thomson Syndrome (RTS)

RTS is a rare autosomal recessive disorder characterized by:

  • Poikiloderma (skin atrophy, pigmentation changes, telangiectasia)
  • Growth retardation
  • Skeletal abnormalities
  • Dental anomalies
  • Increased cancer risk

The syndrome is often linked to mutations in the RECQL4 gene, although some clinically diagnosed patients do not show detectable mutations.

Two Siblings, Distinct Endocrine Patterns

Both siblings demonstrated:

  • Severe growth failure (<3rd percentile)
  • Poikiloderma affecting face and extremities
  • Microdontia and delayed tooth development
  • Dystrophic nails
  • Leukopenia

However, their endocrine abnormalities differed significantly.

Endocrine Findings in the Female Patient

The 14-year-old female presented with

  • Hashimoto’s thyroiditis
  • Elevated anti-thyroid peroxidase (Anti-TPO) antibodies
  • Severe hypothyroidism requiring thyroxine therapy
  • Normal onset of menarche after treatment

Endocrine Findings in the Male Patient

  • Hypergonadotropic hypogonadism
  • Elevated LH and FSH levels
  • Low plasma testosterone
  • Small testicular volume
  • No response to stimulation therapy

Primary hypogonadism has been documented in RTS, but persistent endocrine failure despite intervention highlights the complexity of hormonal involvement. The Endocrine Society emphasizes that early diagnosis and hormonal evaluation are crucial in rare genetic syndromes presenting with delayed puberty or gonadal dysfunction.

Why These Findings Matter

  • RTS may present with autoimmune thyroid disease
  • Hypogonadism can be progressive and treatment resistant
  • Regular endocrine screening is essential in RTS management
  • Multidisciplinary monitoring reduces long term risks
  • Despite the absence of detectable RECQL4 mutations in both siblings, the clinical presentation strongly supported RTS diagnosis.

Broader Clinical Implications

RTS patients also face increased risks of

  • Osteosarcoma
  • Skin malignancies
  • Myelodysplastic syndrome
  • Squamous cell carcinoma

Key Takeaways

  • RTS is more than a dermatological condition
  • Endocrine abnormalities may include hypothyroidism and hypogonadism
  • Genetic testing may not always confirm diagnosis
  • Early hormonal evaluation improves patient outcomes
  • Long-term malignancy monitoring is essentia

Call to Action

Disclaimer: This content is generated using AI assistance and should be reviewed for accuracy and compliance before considering this article and its contents as a reference. Any mishaps or grievances raised due to the reusing of this material will not be handled by the author of this article.